KR20010102943A - 결합 조직 성장 인자(ctgf) 및 그의 이용 방법 - Google Patents

결합 조직 성장 인자(ctgf) 및 그의 이용 방법 Download PDF

Info

Publication number
KR20010102943A
KR20010102943A KR1020017005703A KR20017005703A KR20010102943A KR 20010102943 A KR20010102943 A KR 20010102943A KR 1020017005703 A KR1020017005703 A KR 1020017005703A KR 20017005703 A KR20017005703 A KR 20017005703A KR 20010102943 A KR20010102943 A KR 20010102943A
Authority
KR
South Korea
Prior art keywords
seq
ctgf
polynucleotide
cell
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020017005703A
Other languages
English (en)
Korean (ko)
Inventor
브라이언 프레데릭 슈미트
마가렛 리어 알렌
프란 스베르드럽
데이비드 에프 카르미카엘
Original Assignee
추후보정
피브로겐, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 추후보정, 피브로겐, 인크. filed Critical 추후보정
Priority claimed from PCT/US1999/026189 external-priority patent/WO2000027868A2/en
Publication of KR20010102943A publication Critical patent/KR20010102943A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
KR1020017005703A 1998-11-06 1999-11-05 결합 조직 성장 인자(ctgf) 및 그의 이용 방법 Withdrawn KR20010102943A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/187,478 1998-11-06
US09/187,478 US6348329B1 (en) 1998-11-06 1998-11-06 Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use
US09/292,036 US6358741B1 (en) 1998-11-06 1999-04-14 Connective tissue growth factor (CTGF) and methods of use
US09/292,036 1999-04-14
PCT/US1999/026189 WO2000027868A2 (en) 1998-11-06 1999-11-05 Connective tissue growth factor (ctgf) and methods of use

Publications (1)

Publication Number Publication Date
KR20010102943A true KR20010102943A (ko) 2001-11-17

Family

ID=22689164

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017005703A Withdrawn KR20010102943A (ko) 1998-11-06 1999-11-05 결합 조직 성장 인자(ctgf) 및 그의 이용 방법

Country Status (4)

Country Link
US (3) US6348329B1 (cg-RX-API-DMAC7.html)
JP (1) JP4698837B2 (cg-RX-API-DMAC7.html)
KR (1) KR20010102943A (cg-RX-API-DMAC7.html)
HK (1) HK1039342A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562618B1 (en) * 1997-12-25 2003-05-13 Japan Tobacco, Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
MXPA01005949A (es) * 1998-12-14 2002-09-18 Univ Miami Fragmentos de factor de crecimiento de tejido conectivo y metodos y usos de los mismos.
US7115390B1 (en) * 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
US6444657B1 (en) * 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
US6965025B2 (en) * 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
EP1616568A3 (en) 2002-04-30 2006-06-21 Alcon, Inc GSK-3 inhibitors and CDK inhibitors as anti-glaucoma agents
EP1497420A4 (en) * 2002-04-30 2005-04-27 Alcon Inc AGENTS THAT REGULATE, RESTRICT OR MODULATE THE ACTIVITY AND / OR EXPRESSION OF BIND WEAVE GROWTH FACTOR (CTGF) AS UNIQUE MEDICAMENTS BOTH TO REDUCE EYESPRINTS AND TREAT GLACCOMPETOSIS RETINOPATHIES / OPTIC NEUROPATHIES
WO2003102161A2 (en) * 2002-06-04 2003-12-11 Metabolex, Inc. Methods of diagnosing & treating diabetes and insulin resistance
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
WO2005033136A1 (en) * 2003-09-29 2005-04-14 Children's Hospital, Inc. Unique integrin binding site in connective tissue growth factor (ctgf)
CA2555789A1 (en) * 2004-02-11 2005-08-25 Fibrogen, Inc. Ctgf as target for the therapy of diabetic nephropathy
TWI386225B (zh) * 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子(CTGF)RNA干擾(RNAi)抑制技術
US20060275797A1 (en) * 2005-03-21 2006-12-07 Alcon Manufacturing, Ltd. Use of agents which inhibit connective tissue growth factor (CTGF) binding and signaling via the TrkA/p75NTR receptor complex for the prevention and treatment of CTGF-mediated ocular disorders
US20100034892A1 (en) 2006-08-30 2010-02-11 The Trustees Of Columbia University In The City Of New York Treatment for bone formation disorders by growth factor delivery
CN107083386A (zh) 2008-08-25 2017-08-22 埃克斯雷德制药有限公司 阻止结缔组织生长因子的反义核苷酸及其用途
US8946172B2 (en) * 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
EP2448971A1 (en) 2009-07-02 2012-05-09 Fibrogen, Inc. Methods for treatment of muscular dystrophy
WO2011056234A1 (en) 2009-11-06 2011-05-12 Fibrogen, Inc. Treatment for radiation-induced disorders
WO2012061811A2 (en) 2010-11-05 2012-05-10 Fibrogen, Inc. Treatment method for lung remodeling diseases
DK2670411T3 (da) 2011-02-02 2019-05-13 Excaliard Pharmaceuticals Inc Antisense-forbindelser rettet mod bindevævsvækstfaktor (CTGF) til anvendelse i en fremgangsmåde til behandling af keloider eller hypertrofiske ar
US8802839B2 (en) 2011-07-15 2014-08-12 Fibrogen, Inc. Connective tissue growth factor antisense oligonucleotides
EP3386544B1 (en) 2015-12-10 2020-11-25 Fibrogen, Inc. Methods for treatment of motor neuron diseases
US20200369759A1 (en) 2019-05-23 2020-11-26 Fibrogen, Inc. Methods of treatment of muscular dystrophies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5094941A (en) 1987-12-31 1992-03-10 Zymogenetics, Inc. Monoclonal antibodies to PDGF
US5147294A (en) 1990-10-01 1992-09-15 Trustees Of Boston University Therapeutic method for reducing chronic pain in a living subject
JPH06503966A (ja) 1990-12-21 1994-05-12 クリエイティブ バイオモレキュルズ インコーポレイテッド 生合成したpdgfアンタゴニスト
US5408040A (en) 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US5770209A (en) 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5596090A (en) * 1992-07-24 1997-01-21 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human VCAM-1 RNA
US5916756A (en) 1993-12-14 1999-06-29 University Of South Florida Assay of connective tissue growth factor for detection of cell proliferative disorders
JP4537507B2 (ja) * 1997-12-25 2010-09-01 アムジェン インコーポレイテッド 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途
US6562618B1 (en) * 1997-12-25 2003-05-13 Japan Tobacco, Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof

Also Published As

Publication number Publication date
HK1039342A1 (zh) 2002-04-19
US6358741B1 (en) 2002-03-19
US20020115156A1 (en) 2002-08-22
JP4698837B2 (ja) 2011-06-08
JP2002529066A (ja) 2002-09-10
US6348329B1 (en) 2002-02-19

Similar Documents

Publication Publication Date Title
JP4698837B2 (ja) 結合組織成長因子(ctgf)および使用方法
US5734039A (en) Antisense oligonucleotides targeting cooperating oncogenes
AU765133B2 (en) Connective tissue growth factor (CTGF) and methods of use
KR100304033B1 (ko) 세포증식질환치료용약제학적조성물
JP3054745B2 (ja) raf遺伝子発現のアンチセンスオリゴヌクレオチド調節
Chen et al. Structure of pp32, an acidic nuclear protein which inhibits oncogene-induced formation of transformed foci.
JPH09507381A (ja) 血管平滑筋細胞の増殖の阻害
JP2003500052A (ja) ヒストン脱アセチル酵素の抑制
AU3121100A (en) Connective tissue growth factor fragments and methods and uses thereof
US6498144B1 (en) Use of scatter factor to enhance angiogenesis
EP0668782B1 (en) Combination of antineoplastic agent and antisense oligonucleotides for treatment of cancer
KR100608276B1 (ko) 동맥경화 및 ptca술후의 혈관 재협착에 대한예방·치료제
JPWO2000010608A1 (ja) 動脈硬化およびptca術後の血管再狭窄に対する予防・治療剤
KR20010043090A (ko) 신규인 폴리펩티드, 그 폴리펩티드를 코드화하는 cDNA및 그 용도
KR100688045B1 (ko) 인테그린 αv-아단위 발현 억제를 위한 안티센스 올리고뉴클레오티드 및 이를 포함하는 약제학적 조성물
US20110287088A1 (en) Modulation of olfml-3 mediated angiogenesis
EP1115386B1 (en) Medicament for the treatment of infection
EP0856052A1 (en) Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate
WO1999046381A9 (en) Human fgf gene and gene expression products
UA75037C2 (en) Inhibitors used for hemostasis and modulation of immune function
MXPA00009974A (en) ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF INTEGRIN&agr;v

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20010507

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid